Key result
Levosimendan fails to reduce all-cause mortality in patients with severe renal insufficiency.
Why the study?
Levosimendan is contraindicated in patients with creatinine clearance below 30 mL/min, and its efficacy and safety in severe renal insufficiency remain unclear.
Does levosimendan reduce mortality in patients with severe renal insufficiency?
Meta-Analysis (n=814)
Does levosimendan reduce mortality in patients with severe renal insufficiency?
Odds Ratio: 1.13 (95% CI 0.66–1.94)
p-value: p=0.67
A meta-analysis found insufficient evidence of a mortality benefit with levosimendan in severe renal insufficiency, supporting the current clinical contraindication for its use in patients with creatinine clearance below 30 mL/min.
No mortality benefit with levosimendan in severe renal insufficiency; confirms contraindication and supports alternatives in this population.
INTRODUCTION: Levosimendan is a calcium-sensitizing inotropic agent recommended for Heart Failure (HF) treatment but contraindicated in patients with Creatinine Clearance (Ccr) below 30 mL/min. This study aims to systematically evaluate its efficacy and safety in patients with severe renal insufficiency. METHODS: A systematic literature search was conducted in PubMed, Embase, and the Cochrane Library. Randomized Controlled Trials (RCTs) and cohort studies comparing the efficacy and safety of levosimendan in patients with severe renal insufficiency were included. Studies reporting outcomes only in patients with normal renal function or those with Ccr greater than 30 mL/min were excluded. The primary outcome was all-cause mortality. RESULTS: A total of 1541 records were identified, and seven studies enrolling 814 patients were included in the meta-analysis. There was no significant difference in all-cause mortality between levosimendan and control groups [odds ratio (OR) 1.13, 95% confidence interval (CI) 0.66 to 1.94, p = 0.67, I2 = 23%]. Subgroup analyses showed no significant differences in 30-day mortality [OR 1.17, 95% CI (0.69, 1.99), p = 0.55, I2 = 15%] or 180-day mortality [OR 1.09, 95% CI (0.39, 13.06), p = 0.87, I2 = 57%]. DISCUSSION: The absence of mortality benefit may reflect levosimendan's altered pharmacokinetics and competing uremic risks in severe renal insufficiency. However, renoprotective mechanisms have been primarily characterized in populations without renal impairment, and the prolonged half-life of OR-1896 in this setting may potentiate both hemodynamic effects and adverse events. CONCLUSION: This study found that available evidence from small, heterogeneous observational studies is insufficient to determine whether levosimendan affects mortality in severe renal insufficiency. These findings do not support any clinical recommendation, provide no basis to modify the existing contraindication for Ccr below 30 mL/min, and highlight the need for further RCTs with comprehensive endpoints.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) conducted a meta-analysis in Severe renal insufficiency (n=814). Levosimendan vs. control was evaluated on All-cause mortality (OR 1.13, 95% CI 0.66-1.94, p=0.67). Levosimendan did not significantly affect all-cause mortality compared to control in patients with severe renal insufficiency (OR 1.13; 95% CI 0.66-1.94; p=0.67).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: